General Information of Drug (ID: DM4AFHY)

Drug Name
PMID26161698-Compound-25 Drug Info
Cross-matching ID
PubChem CID
71618654
TTD Drug ID
DM4AFHY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [2]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [3]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [6]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [2]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [2]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [8]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [11]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [12]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [13]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [1]

References

1 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
4 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
5 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
6 Clinical pipeline report, company report or official report of BioTheryX.
7 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
8 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
9 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
10 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
11 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
12 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
13 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
14 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
15 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.